HLX01
Sponsors
Shanghai Henlius Biotech
Conditions
B-cell LymphomasB-cell Non Hodgkin's LymphomaCD20-positive Follicular Lymphoma, With Low Tumour BurdenModerately to Severely Active Rheumatoid ArthritisRheumatoid Arthritis
Phase 1
A Pharmacokinetic and Pharmacodynamic Study Comparing HLX01 And Rituximab in Patients With CD20-Positive, B-cell Lymphoma
CompletedNCT02584920
Start: 2014-10-31End: 2015-08-31Updated: 2022-05-09
A Study to Evaluate Safety, Tolerability, PK and PD of HLX01 in Patients With CD20-positive B-cell Lymphomas
CompletedNCT03218072
Start: 2014-05-04End: 2015-01-31Updated: 2022-05-09
A Randomised, Double-blind, Phase I/II Study to Evaluate the PK, PD, Safety, and Efficacy Between HLX01 and Rituximab in Patients With Moderate to Severe Rheumatoid Arthritis and Inadequate Response to Treatment With DMARDs
CompletedNCT03355872
Start: 2016-02-29End: 2018-08-31Updated: 2022-05-09
Phase 3
Clinical Study to Compare the Efficacy and Safety of Rituximab Biosimilar HLX01 and Rituximab in Combination With CHOP, in Previously Untreated Subjects With CD20+ DLBCL
CompletedNCT02787239
Start: 2015-10-31End: 2018-05-31Updated: 2022-05-09
Study of Safety and Efficacy of HLX01+MTX in Patients With Rheumatoid Arthritis
CompletedNCT03522415
Start: 2018-05-28End: 2020-09-11Updated: 2022-05-09
Evaluate the Efficacy and Safety of HLX01 Versus Mabthera in Patients With Low Tumour Burden Follicular Lymphoma.
WithdrawnNCT04671420
Start: 2020-10-31End: 2022-10-31Updated: 2020-12-17